论文信息 - Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. - 字舞流文

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

S. Opal | R. Greenman | C. Fisher | G. Slotman | R. Balk | E. Rackow | J. Dhainaut | T. J. Iberti | J. Pribble | M. Shapiro | C. J. Fisher | R. A. Balk